Consensus on surgical technique for sentinel lymph node dissection in cervical cancer.

Cervical Cancer Laparoscopes Sentinel Lymph Node

Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
20 Feb 2024
Historique:
medline: 21 2 2024
pubmed: 21 2 2024
entrez: 20 2 2024
Statut: aheadofprint

Résumé

The purpose of this study was to establish a consensus on the surgical technique for sentinel lymph node (SLN) dissection in cervical cancer. A 26 question survey was emailed to international expert gynecological oncology surgeons. A two-step modified Delphi method was used to establish consensus. After a first round of online survey, the questions were amended and a second round, along with semistructured interviews was performed. Consensus was defined using a 70% cut-off for agreement. Twenty-five of 38 (65.8%) experts responded to the first and second rounds of the online survey. Agreement ≥70% was reached for 13 (50.0%) questions in the first round and for 15 (57.7%) in the final round. Consensus agreement identified 15 recommended, three optional, and five not recommended steps. Experts agreed on the following recommended procedures: use of indocyanine green as a tracer; superficial (with or without deep) injection at 3 and 9 o'clock; injection at the margins of uninvolved mucosa avoiding vaginal fornices; grasping the cervix with forceps only in part of the cervix is free of tumor; use of a minimally invasive approach for SLN biopsy in the case of simple trachelectomy/conization; identification of the ureter, obliterated umbilical artery, and external iliac vessels before SLN excision; commencing the dissection at the level of the uterine artery and continuing laterally; and completing dissection in one hemi-pelvis before proceeding to the contralateral side. Consensus was also reached in recommending against injection at 6 and 12 o'clock, and injection directly into the tumor in cases of the tumor completely replacing the cervix; against removal of nodes through port without protective maneuvers; absence of an ultrastaging protocol; and against modifying tracer concentration at the time of re-injection after mapping failure. Recommended, optional, and not recommended steps of SLN dissection in cervical cancer have been identified based on consensus among international experts. These represent a surgical guide that may be used by surgeons in clinical trials and for quality assurance in routine practice.

Identifiants

pubmed: 38378695
pii: ijgc-2023-005151
doi: 10.1136/ijgc-2023-005151
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Nicolò Bizzarri (N)

UOC Ginecologia Oncologica, Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy nicolo.bizzarri@yahoo.com.

Andreas Obermair (A)

Queensland Centre for Gynaecological Cancer Research, Faculty of Medicine, Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia.

Heng-Cheng Hsu (HC)

Obstetrics and Gynaecology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.

Enrique Chacon (E)

Gynaecologic Oncology, Universidad de Navarra, Pamplona, Spain.

Anna Collins (A)

Obstetrics and Gynaecology, Derby Hospitals NHS Foundation Trust, Derby, UK.

Irina Tsibulak (I)

Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Innsbruck, Austria.

Alex Mutombo (A)

Gynaecology and Obstetrics, University of Kinshasa, Kinshasa, Congo (Democratic Republic of the).

Nadeem R Abu-Rustum (NR)

Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

Vincent Balaya (V)

Department of Obstetrics and Gynaecology, Felix Guyon Hospital, CHU Nord Réunion, France.

Alessandro Buda (A)

Gynaecologic Oncology, Ospedale Michele e Pietro Ferrero, Verduno, Italy.

David Cibula (D)

Department of Obstetrics and Gynecology, Charles University, First Faculty of Medicine, Prague, Czech Republic.

Allan Covens (A)

Gynecologic Oncology, Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada.

Francesco Fanfani (F)

UOC Ginecologia Oncologica, Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Gwenaël Ferron (G)

Department of Surgical Oncology, Institut Claudius Regaud Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.

Michael Frumovitz (M)

Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Benedetta Guani (B)

Department of Obstetrics and Gynaecology, Fribourg Hospitals, Fribourg, Switzerland.

Roman Kocian (R)

Department of Obstetrics and Gynecology, Charles University, First Faculty of Medicine, Prague, Czech Republic.

Christhardt Kohler (C)

Department of Gynaecology, University of Cologne, Koln, Germany.
Department of Special Operative and Oncologic Gynaecology, Asklepios-Clinic Hamburg-Altona, Asklepios Hospital Group, Hamburg, Germany.

Eric Leblanc (E)

Department of Surgical Oncology, Centre Oscar Lambret, Lille, France.

Fabrice Lecuru (F)

Breast, Gynaecology, and Reconstructive Surgery Unit, Institute Curie, Paris, France.

Mario M Leitao (MM)

Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

Patrice Mathevet (P)

Centre Hospitalier Universitaire Vaudois Departement de gynecologie-obstetrique et genetique medicale, Lausanne, Switzerland.

Michael D Mueller (MD)

Gynaecology and Gynaecological Oncology, Inselspital University Hospital Berne Department of Gynaecology, Bern, Switzerland.

Andrea Papadia (A)

Department of Gynaecology and Obstetrics, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Università della Svizzera italiana, Lugano, Switzerland.

Rene Pareja (R)

Department of Gynaecology, Gynaecologic Oncology, Clinica Astorga, Medellin, Colombia.
Instituto Nacional de Cancerología, Bogotá, Colombia.

Marie Plante (M)

Laval University, Quebec City, Quebec, Canada.

Denis Querleu (D)

UOC Ginecologia Oncologica, Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Giovanni Scambia (G)

UOC Ginecologia Oncologica, Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Edward Tanner (E)

Department of Obstetrics and Gynecology, Northwestern University, Evanston, Illinois, USA.

Ignacio Zapardiel (I)

Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain.

Jaime R Garcia (JR)

Department of Academic Analytics and Technology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Pedro T Ramirez (PT)

Department of Obstetrics and Gynecology, Houston Methodist Hospital, Houston, Texas, USA.

Classifications MeSH